Clinical trials: Hypersplenism, active
Extrahepatic Portal Vein Obstruction (EHPVO), Thrombophilia
Hematological Disorders in EHPVO Patients
This study focuses on patients who have a condition called extrahepatic portal vein obstruction (EHPVO), where a blood clot blocks the portal vein outside the liver.
- Conditions
- Extrahepatic Portal Vein Obstruction (EHPVO), Thrombophilia, Myeloproliferative Neoplasms (MPN), Antiphospholipid Syndrome (APS)
- Trial name
- EHPVO-HEM (NCT07108023)
- Testing
- No intervention (Observational Study)
- Volunteers
- 115 people
- Sponsor
- Rahab Nady
Cirrhoses, Liver, Splenectomy; Status
Laparoscopic Partial Splenectomy for Hypersplenism in Liver Cirrhosis Patients
In this study,the researchers compared the changes in immune function-related indicators in patients with liver cirrhosis following laparoscopic partial splenectomy,to determine whether this surgical intervention can enhance…
- Conditions
- Cirrhoses, Liver, Splenectomy; Status, Partial
- Trial name
- LPSH (NCT07205471)
- Testing
- Laparoscopic Partial Splenectomy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Northern Jiangsu People's Hospital
Cirrhosis, Hypersplenism
Vagus Nerve-guided Laparoscopic Splenectomy and Azygoportal Disconnection
This study aimed to evaluate the effectiveness and safety of vagus nerve-guided laparoscopic splenectomy and azygoportal disconnection, and to assess its impact on postoperative digestive complications and quality of life.
- Conditions
- Cirrhosis, Hypersplenism, Hypertension, Portal
- Trial name
- VNLSD (NCT07462091)
- Testing
- Vagus nerve-guided laparoscopic splenectomy and azygoportal disconnection
- Where
- 2 sites in China
- Volunteers
- 15 people
- Sponsor
- Northern Jiangsu People's Hospital
Liver Cirrhosis, HCC - Hepatocellular Carcinoma
Effect of Laparoscopic Hepatectomy Combined With Splenectomy on Hepatic Functional Reserve and Immune Function
Splenectomy may relieve hypersplenism, reverse liver fibrosis, improve hepatic functional reserve, and reshape the systemic antitumor immune milieu by removing the source of negative immunomodulation.
- Conditions
- Liver Cirrhosis, HCC - Hepatocellular Carcinoma, Hypersplenism
- Trial name
- LHCS-HFRI (NCT07811687)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Northern Jiangsu People's Hospital
Liver Cirrhosis
Long-term Efficacy and Safety of LSD Versus TIPS for Cirrhotic Portal Hypertension Bleeding and Hypersplenism
This study aims to compare two treatments for cirrhotic portal hypertension with acute esophagogastric variceal bleeding and hypersplenism: laparoscopic splenectomy and azygoportal disconnection (LSD) and transjugular…
- Trial name
- LSD、TIPS (NCT07490405)
- Testing
- LSD, TIPS
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Northern Jiangsu People's Hospital
Cirrhosis, Splenectomy
Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD
The purpose of this study is to determine whether Apixaban is effective and safe in the treatment of portal vein thrombosis Occurring more than one year after laparoscopic splenectomy and azygoportal disconnection.
- Conditions
- Cirrhosis, Splenectomy, Portal Vein Thrombosis, Hypertension, Portal
- Trial name
- NCT07461532
- Testing
- Apixaban 2.5 MG
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Northern Jiangsu People's Hospital
Cirrhosis, Liver, Splenectomy; Status
Effect of LSD on Lipid Profiles in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up)
Patients with liver cirrhosis frequently exhibit dyslipidemia due to impaired hepatic lipid synthesis, altered bile acid metabolism, and portal hypertension.
- Conditions
- Cirrhosis, Liver, Splenectomy; Status, Portal Hypertension, Lipid Profiles
- Trial name
- LSD-LPPH (NCT07588334)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Northern Jiangsu People's Hospital
Cirrhosis, Splenectomy; Status
Effect of Laparoscopic Splenectomy on Renal Function in Cirrhotic Patients With Hypersplenism (2-Year Follow-Up)
Patients with liver cirrhosis often have impaired or at-risk kidney function due to the close link between liver and kidney (hepatorenal syndrome).
- Conditions
- Cirrhosis, Splenectomy; Status, Hypersplenism, Kidney Function Issue
- Trial name
- LS-RF (NCT07585773)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Northern Jiangsu People's Hospital
Secondary Hypersplenism
A Single-Arm Clinical Trial of Percutaneous Splenic Ablation Combined With Splenic Artery Occlusion for Secondary Hypersplenism.
This study assesses the effectiveness of microwave ablation of the spleen in conjunction with splenic artery occlusion for treating secondary hypersplenism.
- Trial name
- NCT06292715
- Testing
- microwave ablation of the spleen, Splenic artery balloon implantation
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Cirrhosis, Splenectomy; Status
Effect of Laparoscopic Splenectomy on Lipid Profiles in Cirrhotic Patients With Hypersplenism (2-Year Follow-Up)
Patients with liver cirrhosis frequently exhibit dyslipidemia due to impaired hepatic lipid synthesis, altered bile acid metabolism, and portal hypertension.
- Conditions
- Cirrhosis, Splenectomy; Status, Hypersplenism, Lipid Profiles
- Trial name
- LS-LP-CH (NCT07588373)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Northern Jiangsu People's Hospital
Autoimmune Lymphoproliferative Syndrome
Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients
Background: Autoimmune lymphoproliferative syndrome (ALPS) is a rare disorder of the immune system caused by a mutation in the FAS gene. In ALPS, the body stores too many germ-fighting cells called lymphocytes.
- Trial name
- NCT06730126
- Testing
- Soquelitinib
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)